Regeneron Earnings: What You Have to Watch (REGN)

Regeneron Earnings: What You Have to Watch

While Regeneron (Nasdaq: REGN ) doesn't rank among top performers in the Nasdaq Composite, its year-to-date performance is still nothing short of impressive. Shares have risen around 180% and boosted the company's market capitalization to nearly $15 billion on the strength of Eylea, the company's flagship drug targeting age-related macular degeneration. The company reports earnings Wednesday, and as is the case for many high flying-stocks, hitting Wall Street's revenue estimates and offering strong guidance for the future will play a vital role in which direction the shares go.

In the following video, health care bureau chief Brenton Flynn outlines the competitive environment for Regeneron's Eylea, including one low-priced drug that could turn out to be its biggest competition.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.